# Annette Bruchfeld

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/annette-bruchfeld/

## Facts

| Field | Value |
| --- | --- |
| Citations | 10,219 |
| Field | Vasculitis and related conditions |
| h-index | 50 |
| i10-index | 133 |
| Last Known Institution | Linköping University |
| OpenAlex ID | https://openalex.org/A5015537437 |
| ORCID iD | 0000-0002-9752-9941 |
| Works | 275 |

## Researcher papers

- [Genetically Distinct Subsets within ANCA-Associated Vasculitis](https://scholariq.org/papers/genetically-distinct-subsets-within-anca-associated-vasculitis/)
- [Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study](https://scholariq.org/papers/grazoprevir-plus-elbasvir-in-treatment-naive-and-treatment-experienced-patients/)
- [Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis](https://scholariq.org/papers/randomized-trial-of-c5a-receptor-inhibitor-avacopan-in-anca-associated/)
- [Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up](https://scholariq.org/papers/pulse-versus-daily-oral-cyclophosphamide-for-induction-of-remission-in-anca/)
- [ELEVATED HIGH-MOBILITY GROUP BOX 1 LEVELS IN PATIENTS WITH CEREBRAL AND MYOCARDIAL ISCHEMIA](https://scholariq.org/papers/elevated-high-mobility-group-box-1-levels-in-patients-with-cerebral-and/)
- [Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial](https://scholariq.org/papers/mycophenolate-mofetil-versus-cyclophosphamide-for-remission-induction-in-anca/)
- [High‐dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C†](https://scholariq.org/papers/high-dose-ribavirin-in-combination-with-standard-dose-peginterferon-for/)
- [Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis](https://scholariq.org/papers/finerenone-in-patients-with-chronic-kidney-disease-and-type-2-diabetes-by-sodium/)
- [Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial](https://scholariq.org/papers/efficacy-and-safety-of-aldosterone-synthase-inhibition-with-and-without/)
- [Plasma Exchange for Renal Vasculitis and Idiopathic Rapidly Progressive Glomerulonephritis: A Meta-analysis](https://scholariq.org/papers/plasma-exchange-for-renal-vasculitis-and-idiopathic-rapidly-progressive/)
- [Management of adult patients with podocytopathies: an update from the ERA Immunonephrology Working Group](https://scholariq.org/papers/management-of-adult-patients-with-podocytopathies-an-update-from-the-era/)

## Researcher topics

- [Vasculitis and related conditions](https://scholariq.org/topics/vasculitis-and-related-conditions/)
- [Hepatitis C virus research](https://scholariq.org/topics/hepatitis-c-virus-research/)
- [Renal Diseases and Glomerulopathies](https://scholariq.org/topics/renal-diseases-and-glomerulopathies/)
- [Otitis Media and Relapsing Polychondritis](https://scholariq.org/topics/otitis-media-and-relapsing-polychondritis/)
- [Systemic Lupus Erythematosus Research](https://scholariq.org/topics/systemic-lupus-erythematosus-research/)

## Researcher university

- [Linköping University](https://scholariq.org/institutions/linkoping-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.